886496-63-5

Basic information

• Product Name: 2-Bromo-5-(trifluoromethyl)benzyl bromide
• Synonyms: 1-Bromo-2-(bromomethyl)-4-(trifluoromethyl)benzene, 4-Bromo-3-(bromomethyl)benzotrifluoride
• CAS NO: 886496-63-5
• Molecular Formula: C₈H₅Br₂F₃
• Molecular Weight: 317.9285096
• Product Categories: Fluorine series
• Mol File: 886496-63-5.mol

Chemical Properties

• Boiling Point: 259℃
• Flash Point: 110℃
• Appearance: /
• Density: 1.885
• Vapor Pressure: 0.0219mmHg at 25°C
• Refractive Index: 1.523
• CAS DataBase Reference: 2-Bromo-5-(trifluoromethyl)benzyl bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-5-(trifluoromethyl)benzyl bromide(886496-63-5)
• EPA Substance Registry System: 2-Bromo-5-(trifluoromethyl)benzyl bromide(886496-63-5)

Safety Data

• Hazardous Substances Data: 886496-63-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-5-(trifluoromethyl)benzyl bromide is used as a reagent for the synthesis of various pharmaceuticals, leveraging its reactivity to introduce bromine and trifluoromethyl groups into organic molecules, which can enhance the pharmacological properties of the resulting compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Bromo-5-(trifluoromethyl)benzyl bromide serves as a reagent in the production of agrochemicals, where its ability to act as a strong halogenating agent is utilized to modify the chemical structure of molecules to improve their effectiveness as pesticides or other agricultural chemicals.
Used as a Strong Halogenating Agent:
2-Bromo-5-(trifluoromethyl)benzyl bromide is used in various chemical reactions as a strong halogenating agent, facilitating the introduction of halogen atoms into organic molecules, which can alter their chemical properties and reactivity.
It is important to handle 2-Bromo-5-(trifluoromethyl)benzyl bromide with care due to its toxic nature and potential to cause skin and eye irritation upon contact. Proper safety measures should be taken during its use in chemical processes.

InChI:InChI=1/C8H5Br2F3/c9-4-5-3-6(8(11,12)13)1-2-7(5)10/h1-3H,4H2

Upstream product

• 929000-62-4 1-bromo-2-methyl-4-(trifluoromethyl)benzene 
• 75-09-2 dichloromethane 
• 402-05-1 2-bromo-5-(trifluoromethyl)phenol 
• 1483-56-3 2-bromo-5-(trifluoromethyl)benzoic acid 
• 869725-53-1 (2-bromo-5-(trifluoromethyl)phenyl)methanol 

Downstream Products

• 16238-03-2 2-phenyl-5-(trifluoromethyl)benzofuran 
• 888738-14-5 N-(2-bromo-5-(trifluoromethyl)benzyl)-N-(3,5-bis(trifluoromethyl)benzyl)-2-methyl-2H-tetrazol-5-amine 
• 1185737-46-5 2-[6-methoxy-2'-((4S,5R)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-ylmethyl)-4'-trifluoromethyl-biphenyl-3-yl]-propionic acid 

Relevant articles and documents

2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS

The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X); wherein Y', X', B', R1', R2', R3', R5', R6', R7', and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.

Oxazolidinone compound as well as preparation method, application and pharmaceutical composition thereof

The invention relates to an oxazolidinone compound used as an Lp-PLA2 covalent inhibitor and a pharmaceutical composition of the oxazolidinone compound, the structure of the oxazolidinone compound isshown as a general formula I, and R1, R2 and R3 are defined as the specification and claims. The compound shown in the general formula I or the stereoisomer or the pharmaceutically acceptable salt thereof can be used as the Lp-PLA2 covalent inhibitor to prevent and/or treat and/or improve diseases related to Lp-PLA2 enzyme activity. Meanwhile, the stereoisomer or the pharmaceutically acceptable salt of the compound shown in the general formula I can be used as an Lp-PLA2 specific molecular probe.

tBuOK-Promoted Cyclization of Imines with Aryl Halides

A transition-metal-free indole synthesis using radical coupling of 2-halotoluenes and imines via the later-stage C-N bond construction was reported for the first time. It includes an aminyl radical generation by C-H cleaving addition of 2-halotoluenes to imines via the carbanion radical relay and an intramolecular coupling of aryl halides with aminyl radicals. One standard condition can be used for all halides including F, Cl, Br, and I. No extra oxidant or transition metal is required.

Cross-coupling strategy for the synthesis of diazocines

Ethylene bridged azobenzenes are novel, promising molecular switches that are thermodynamically more stable in the (Z) than in the (E) configuration, contrary to the linear azobenzene. However, their previous synthetic routes were often not general, and yields were poorly reproducible, and sometimes very low. Here we present a new synthetic strategy that is both versatile and reliable. Starting from widely available 2-bromobenzyl bromides, the designated molecules can be obtained in three simple steps.

Strategy for Overcoming Full Reversibility of Intermolecular Radical Addition to Aldehydes: Tandem C-H and C-O Bonds Cleaving Cyclization of (Phenoxymethyl)arenes with Carbonyls to Benzofurans

An intermolecular addition of carbon radicals enabled by a cascade radical coupling strategy is developed. It includes an intermolecular alkyl radical addition to a carbonyl group followed by an intramolecular alkoxy radical addition to haloarenes and produces substituted benzofurans in high yields. The radical nature of this reaction is explored by radical trapping experiments and EPR analysis. The mechanism is investigated by KIE experiments and control experiments. This method could provide rapid and practical access to the key intermediate of TAM-16, a safe and potent antibacterial agent for treating tuberculosis, and, therefore, is of great importance for organic synthesis and the pharmaceutical industry.

COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

Disclosed herein are cannabinoid receptor ligands of formula (1) wherein Ring A and R1 are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also described

Synthesis of benzylisoquinoline derivatives possessing electron-withdrawing substituents on the benzene ring of the isoquinoline skeleton

3,4-Dihydrobenzylisoquinolines and 1,2,3,4-tetrahydrobenzyl-isoquinolines possessing electron withdrawing substituents on the benzene ring of the isoquinoline framework are easily accessible by a synthetic approach that takes advantage of a Sonogashira coupling to build up the C1-C8a bond of the isoquinoline skeleton and a Ti-catalyzed intramolecular hydroamination of an alkyne to close the heterocyclic ring.

Dibenzyl Amine Compounds and Derivatives

Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid le

Dibenzyl Amine Compounds and Derivatives

Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

DIBENZYL AMINE COMPOUNDS AND DERIVATIVES

Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid le